Innate Pharma SA (IPHA) Institutional Ownership

Ownership Summary

Innate Pharma SA (NASDAQ:IPHA) currently has 3 active institutional owners and shareholders as of today (December 2025), that have filed 13F forms with the Securities Exchange Commission (SEC).

• These investors collectively held 0.0% of the company's total shares outstanding in December 2025, down from 0.1% in September 2025.
• The company experienced a -71.36% quarterly change in institutional shares held, alongside a decrease of 70.00% in total owners annually.
• The latest 13F cycle for Innate Pharma reveals that of 3 total investors, 0 funds grew their exposure, whereas 2 reduced theirs and 1 made no changes.
• This class of investors decreased its holdings in Innate Pharma to 2.03K shares for the 13F-cycle ending December 2025, down by 5.06K shares quarter on quarter, and down 135.94K shares year over year.
• As of December 31, 2025, GAMMA Investing LLC held Innate Pharma's largest shareholding position with over 1.07K shares, representing 0.00% of total outstanding shares.
• Leading sellers of Innate Pharma stock in December 2025 included UBS Group AG (3.85K), GAMMA Investing LLC (1.21K).
• The top 3 institutional holders of Innate Pharma for the quarter ending December 2025 included GAMMA Investing LLC (1.07K), UBS Group AG (947), Farther Finance Advisors, LLC (10).